Pharmafile Logo
Pharmafocus logo
Advanced Search

Cancer

Showing 15 posts of 1067 posts found.

roche__tree

EU approval for Roche’s Polivy combo in relapsed/refractory B-cell lymphoma

January 21, 2020
Manufacturing and Production, Sales and Marketing Cancer, Polivy, Roche, lymphoma, pharma

The European Commission has awarded conditional marketing approval to Roche’s Polivy (polatuzumab vedotin), it has been revealed.

News
29419203133_3c3c14e63e_z

Cardiff University team discovers new method of killing cancers

January 21, 2020
Manufacturing and Production Cancer, Cancer cures, Cancerous, Cardiff University, T cell, cells, immune system, immunity, t-cell

A team at Cardiff University have discovered a new part of the human immune system that could be harnessed to …

News
fda2outsideweb

Lynparza secures accelerated FDA review for metastatic castration-resistant prostate cancer

January 20, 2020
Sales and Marketing Cancer, FDA, lynparza, pharma

Following the recommendation of the tablet formulation of the drug for use on the NHS in England and Wales, news …

News

NICE turns down Bayer’s tumour-agnostic therapy Vitrakvi over evidence concerns

January 20, 2020
Sales and Marketing Bayer, Cancer, NICE, Vitravki

UK drug watchdog NICE has turned down Bayer’s Vitrakvi (larotrectinib) as a tumour-agnostic treatment solution on the NHS after it …

News

NICE shoots down Keytruda in head and neck cancer over data concerns

January 16, 2020
Sales and Marketing Cancer, NHS, NICE, UK, keytruda, pharma

It has been revealed that NICE has chosen to reject MSD’s blockbuster immunotherapy Keytruda (pembrolizumab) for routine use on the …

News
zytiga_outside

NHS Scotland recommends Janssen’s Zytiga combo for newly diagnosed prostate cancer

January 13, 2020
Sales and Marketing Cancer, NHS, Scotland, nhs scotland, prostate cancer

Janssen’s Zytiga (abiraterone acetate) has just been approved by the Scottish Medicines Consortium (SMC), meaning that male patients on the …

News

US approval for Blueprint Medicines’ gastrointestinal stromal tumour therapy

January 10, 2020
Medical Communications, Sales and Marketing Ayvakit, Blueprint Medicines, Cancer, pharma

The FDA has moved to authorise Blueprint Medicines’ kinase inhibitor Ayvakit (avapritinib) for the treatment of unresectable or metastatic gastrointestinal …

News
merck-keytruda

MSD’s Keytruda chalks up bladder cancer approval in the US

January 9, 2020
Sales and Marketing Cancer, MSD, bladder cancer, keytruda, pharma

MSD’s blockbuster immunotherapy Keytruda (pembrolizumab) has added another US approval to its repertoire with the news that FDA has awarded …

News
smoking-1026556_1280

Largest drop ever in US cancer mortality rates, new study shows

January 9, 2020
Business Services Cancer, brain cancer, lung cancer, prostate cancer

The overall cancer mortality rate in the US fell by 2.2% from 2016 to 2017, the largest ever annual decline …

News

Single cycle of chemo is just as effective as two in treating testicular cancer, study finds

January 3, 2020
Medical Communications Cancer, Men's Cancer, chemo, chemotherapy, testicular cancer

A new study shows that testicular cancer can be successfully treated with less rounds of chemotherapy. The recent study, published …

News
42271822770_6d2a1d533f_b

AI is more accurate than doctors at diagnosing breast cancer, study finds

January 2, 2020
Business Services AI, AI Cancer, AI Trials, AI diagnoses, AI in clinical trials, Cancer, breast cancer

A recent study showed that Artificial Intelligence is more accurate than doctors in diagnosing breast cancer from mammograms. The research …

News
astrazeneca_sign_sky

FDA gives accelerated approval to AstraZeneca and Daiichi’s breast cancer drug

December 23, 2019
Sales and Marketing AstraZeneca, Breast Cancer drug, Cancer, breast cancer, skin cancer

The FDA has approved the breast cancer drug Enhertu, developed by AstraZeneca and Daiichi Sankyo. José Basel, the Executive Vice …

News
astrazeneca_plaque

AstraZeneca sells Amrimidx and Casodex European rights to Juvisé Pharmaceuticals

December 20, 2019
Medical Communications AstraZeneca, Cancer, Juvise, breast cancer, prostate cancer

AstraZeneca has announced that it has agreed to sell the rights to Arimidex (anastrozole) and Casodex (bicalutamide) in Europe, as …

News
astellas_tokyo_copy_9

FDA approves Seattle Genetics and Astellas Pharma’s bladder cancer drug

December 19, 2019
Business Services Astellas Pharma, Cancer, Padcev, Seattle Genetics, bladder cancer

The FDA has granted accelerated approval for Seattle Genetics and Astellas Pharma’s bladder cancer drug Padcev (enfortumab vedotin-ejfv). The drug’s …

News
5204602349_c87b204860_b

FDA advisory committee approves the use of Lynparza in pancreatic cancer

December 18, 2019
Research and Development AstraZeneca, Cancer, Merck, Pancreatic cancer, lynparza

The FDA’s Oncologic Drugs Advisory Committee (ODAC) has recommended the approval of AstraZeneca and Merck’s Lynparza (olaparib) to treat pancreatic …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026